A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 253 participants.
Also called NCT01729871
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 253 participants
- Registry
-
NCT01729871 -
2012-001484-79
-
- Other papers using this trial's data
- Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, France, Germany, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01729871. Randomized; no masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2014-10 (actual). Results posted on 2015-11-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy
- Acronym
- VENTURE-AF
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- rivaroxaban
- Intervention (Drug)
- uninterrupted vitamin K antagonist (VKA)
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct01729871- Content hash
d9ebad36282b7cc6d6e98cc84a49f833772b1f122f30b1736aa42021a4ddab72